[Positive ionotropic substances (digitoxin and digoxin). Principles and rules of use].
Gelu
M
M
Centre d'investigation clinique, CHU-INSERM, Hôpital cardiologique, Laboratoire de pharmacologie, faculté de médecine, Lille.
Caron
J
J
Libersa
C
C
D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004074:Digitoxin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004077:Digoxin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D062787:Drug Overdose / Q000517:prevention & control; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D012307:Risk Factors; D013617:Tachycardia, Supraventricular / Q000209:etiology*
D002316:Cardiotonic Agents; D004077:Digoxin; D004074:Digitoxin